Satoru Health

Specialist-level obesity care, at the scale of the need

GLP-1 medications work. Health systems are not set up to deliver them. We are working to change that.

The gap

Patients who qualify for GLP-1 therapy are often not treated on indication. Many prescribers avoid GLP-1 care because of its complexity.

Semaglutide, cardiovascular indication
8.9M
eligible
<200K
treated on indication
Bar drawn to scale. Do et al., JACC: Advances, 2026
Outcomes halved
outside specialist care
Specialist care11.5 kg
Primary care5.4 kg
Weight loss at one year. Griauzde et al., Obesity Science & Practice, 2026

The constraint is delivery, not demand.

Our goal
1
Scale treatment of obesity and cardiometabolic disease to the need of the population
2
without overburdening the economy, the health system, or clinicians
3
while providing specialist-level care
What it means

For patients

  • Start therapy sooner
  • Stay on therapy
  • Specialist-level outcomes

For clinicians

  • Eliminate the burden of management
  • More patients treated, no added workload

For health systems

  • Patients stay within the health system
  • Designed to cost about one fifth of today's care
  • Designed to fund itself and scale
Who we are

Lee Kaplan, MD, PhD

Chairman and Chief Science Officer

Forty years at Massachusetts General Hospital and Harvard Medical School. Past President of The Obesity Society.

Yoav Ezer

President and Chief Executive Officer

Twelve years developing a behavioral methodology for the treatment of disordered eating. Two-time software founder.